Floatz logo

Pirfenidone

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

160 Active assets in the To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Mayo Clinic
Phase 2BBB
FLUOROURACILUM
City of Hope Medical Center
Phase 4BB
Eloxatin
First Affiliated Hospital of Zhejiang University
Phase 4BB
MITOMYCIN C
City of Hope Medical Center
Phase 3BB
Capecitabine
First Affiliated Hospital of Zhejiang University
Phase 4BB

View all 50 →

Same molecule, other indications

Pirfenidone is also rated in:

idiopathic pulmonary fibrosisDormant
A
Indicative ·
80 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
66 / 100
View asset →
fibrotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →